Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene & immune-therapies. SVac is safe, non-immunogenic & vector particles can be produced cost effectively in our SuperVero packaging cell line. Based on its unique properties SVac is ideally suited for developing next generation effective gene & immune-ther...
Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene & immune-therapies. SVac is safe, non-immunogenic & vector particles can be produced cost effectively in our SuperVero packaging cell line. Based on its unique properties SVac is ideally suited for developing next generation effective gene & immune-therapies. In order to realize our ambition to become the leading global gene therapy company we formed a worldwide consortium of key players in the virology, oncology, neurology, immunology, ophthalmology.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.